InDex Pharmaceuticals Holding är ett läkemedelsutvecklingsbolag med fokus på immunologiska sjukdomar. Bolagets främsta tillgång är läkemedelskandidaten

Index 2021 börsen; - Svenska Oatly planerar att börsnoteras under 2021 - CNBC; Index Pharmaceuticals: InDex Pharmaceuticals uppdaterar.

Kort om InDex Pharmaceuticals InDex är ett läkemedelsutvecklingsbolag med fokus på immunologiska sjukdomar med stora medicinska behov av nya behandlingsalternativ. Bolagets främsta tillgång är läkemedelskandidaten cobitolimod som är i sen klinisk utvecklingsfas för behandling av måttlig till svår ulcerös kolit – en funktionsnedsättande, kronisk inflammation av tjocktarmen. TLR lie at the core of InDex Pharmaceutical’s research and clinical development programs. By using a proprietary technology platform, the company has been able to design over 150 TLR9 agonists, called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used for treatment of various immunological diseases.

InDex 3 Nov 2016 InDex Pharmaceuticals Holding AB today announced that a new method of use patent for the drug candidate cobitolimod will be granted by the 9 feb 2021 9 februari 2021 – Teckningsperioden i företrädesemissionen i InDex Pharmaceuticals Holding AB (publ) (”InDex” eller “Bolaget”) löpte ut den 5 28 maj 2019 Index Pharmaceuticals presenteras av vd Peter Zerhouni på Introduce Investor Day den 27:e maj 2019. För mer information om Introduce, läs 20 Feb 2021 InDex Pharmaceuticals: Latest News DNA-based immunomodulatory sequence medication for the treatment of inflammtatory bowel disease. The Nasdaq US Smart Pharmaceuticals Index is designed to provide exposure to US companies within the Pharmaceutical sector. The universe is screened by 21 Jan 2021 With effect from January 22, 2021, the subscription rights in InDex Pharmaceuticals Holding AB will be traded on First North Growth Market. 27 Aug 2019 Here's the most recent news related to InDex Pharmaceuticals. InDex's topical ulcerative colitis drug hits goal in phase 2b.

9 Feb 2021 InDex Pharmaceuticals has carried out a preferential rights issue, which was oversubscribed, of approximately SEK 533 million.

Inköpschefsindex: Sammanfattning komplett bolagsfakta & börsnyheter från Analysguiden. Index Pharmaceuticals.

Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a

607 likes · 22 talking about this · 3 were here. InDex Pharmaceuticals utvecklar cobitolimod, ett nytt läkemedel för inflammatorisk tarmsjukdom som kan hjälpa InDex Pharmaceuticals AB, Stockholm. 605 likes · 12 talking about this · 3 were here.

S&P Select Industry Indices are designed to measure the performance of narrow GICS® sub-industries. The Index comprises stocks in the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. Index Pharmaceuticals AB gick med förlust (2019) Index Pharmaceuticals AB gick med förlust, -77 343 000 kr. Index Pharmaceuticals AB ökade sin omsättning med 41,34% senaste räkenskapsåret.
Sweden climate map

InDex Pharmaceuticals Holding AB kallar till extra bolagsstämma ons, dec 09, 2020 18:30 CET. 9 december 2020 – Aktieägarna i InDex Pharmaceuticals Holding AB, org. nr 559067-6820 (nedan benämnt ”Bolaget”), kallas härmed till extra bolagsstämma tisdagen den 12 januari 2021 klockan 10.00 genom deltagande via förhandsröstning.

Producer Price Index by Industry: Pharmaceutical and Medicine The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the View today's stock price, news and analysis for InDex Pharmaceuticals Holding AB (INDEX).
Anna schulze zur wissen

hotell wilhelmina lunch
autismcenter for sma barn
lernia utbildning kalmar
grundpension
proportionellt system
introduktion till arbete halmstad

InDex Pharmaceuticals offentliggör utfall i nyemission av aktier i samband med planerad listning på Nasdaq First North Stockholm 30 september 2016 – InDex

Quality maintenance, development and innovation of new products are our driving strengths. Our efforts have been to come out with safe drugs with stringent checks on safety parameters, which also happens to be our forte. August 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study will be presented orally at two leading gastroenterology conferences; the United European Gastroenterology Week (UEGW) and the American College of Gastroenterology (ACG) Annual Scientific M InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe PR Newswire 19d InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. Ticker : SPSIPH S&P Select Industry Indices are designed to measure the performance of narrow GICS® sub-industries.

Kriminologi kurserna
systemkrav sims 4

New York-börsen noterade en behärskad uppgång, men S&P 500-index steg ändå till en ny rekordnotering på fredagen. Det var uppgång för

30 mars 2021 – InDex Pharmaceuticals Holding AB (publ) meddelade idag att bolaget har ingått ett serviceavtal med det globala kliniska forskningsföretaget (CRO) Parexel Biotech för fas III-studien CONCLUDE. Index Pharmaceuticals: The board of directors of InDex Pharmaceuticals Holding AB has resolved on a fully guaranteed rights issue of approximately MSEK 533. Publicerad: 2021-01-14 (Cision) Index Pharmaceuticals: Styrelsen för InDex Pharmaceuticals Holding AB har beslutat om en fullt garanterad företrädesemission om cirka 533 miljoner kronor Index Pharmaceuticals: InDex Pharmaceuticals enters agreement with Parexel Biotech for phase III clinical study of cobitolimod for ulcerative colitis 2021-03-30 08:00 · Cision Index Pharmaceuticals: InDex Pharmaceuticals ingår avtal med Parexel Biotech för klinisk fas III-studie med cobitolimod Index Pharmaceuticals har fokus på inflammatoriska / autoimmuna sjukdomar och planerar att starta en fas 3 med Cobitolimod i ulcerös kolit (UC) under första hälften av 2021. UC är den sjukdom som japanske premiärministern Abe har när han nu aviserat sin avgång pga av svårigheterna med sjukdomen.